297 related articles for article (PubMed ID: 31176533)
1. Acute ischemic colitis with hematochezia related to baloxavir marboxil treatment for influenza A.
Kanai N; Hashimoto T; Fukuda M; Shijyo T
J Infect Chemother; 2019 Dec; 25(12):1040-1042. PubMed ID: 31176533
[TBL] [Abstract][Full Text] [Related]
2. Baloxavir marboxil (Xofluza) for treatment of influenza.
Med Lett Drugs Ther; 2018 Dec; 60(1561):193-196. PubMed ID: 30653474
[No Abstract] [Full Text] [Related]
3. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
Hayden FG; Sugaya N; Hirotsu N; Lee N; de Jong MD; Hurt AC; Ishida T; Sekino H; Yamada K; Portsmouth S; Kawaguchi K; Shishido T; Arai M; Tsuchiya K; Uehara T; Watanabe A;
N Engl J Med; 2018 Sep; 379(10):913-923. PubMed ID: 30184455
[TBL] [Abstract][Full Text] [Related]
4. Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings.
Koshimichi H; Ishibashi T; Kawaguchi N; Sato C; Kawasaki A; Wajima T
Clin Drug Investig; 2018 Dec; 38(12):1189-1196. PubMed ID: 30288682
[TBL] [Abstract][Full Text] [Related]
5. Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza.
Yang T
Ann Pharmacother; 2019 Jul; 53(7):754-759. PubMed ID: 30674196
[TBL] [Abstract][Full Text] [Related]
6. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts.
Ikematsu H; Hayden FG; Kawaguchi K; Kinoshita M; de Jong MD; Lee N; Takashima S; Noshi T; Tsuchiya K; Uehara T
N Engl J Med; 2020 Jul; 383(4):309-320. PubMed ID: 32640124
[TBL] [Abstract][Full Text] [Related]
7. Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system.
Li Y; Wang X; Liao Y; Zeng Y; Lin W; Zhuang W
BMC Infect Dis; 2024 May; 24(1):446. PubMed ID: 38724914
[TBL] [Abstract][Full Text] [Related]
8. A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients.
Taieb V; Ikeoka H; Ma FF; Borkowska K; Aballéa S; Tone K; Hirotsu N
Curr Med Res Opin; 2019 Aug; 35(8):1355-1364. PubMed ID: 30810054
[No Abstract] [Full Text] [Related]
9. A retrospective observational study of the treatment of a nosocomial infection caused by oseltamivir-resistant influenza virus A with baloxavir marboxil.
Fujita M; Matsumoto H; Inafuku Y; Toyama J; Fujita J
Respir Investig; 2020 Sep; 58(5):403-408. PubMed ID: 32605828
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.
Fukao K; Noshi T; Yamamoto A; Kitano M; Ando Y; Noda T; Baba K; Matsumoto K; Higuchi N; Ikeda M; Shishido T; Naito A
J Antimicrob Chemother; 2019 Mar; 74(3):654-662. PubMed ID: 30476172
[TBL] [Abstract][Full Text] [Related]
11. Baloxavir marboxil: a novel cap-dependent endonuclease (CEN) inhibitor for the treatment of acute uncomplicated influenza.
Locke SC; Splawn LM; Cho JC
Drugs Today (Barc); 2019 Jun; 55(6):359-366. PubMed ID: 31250840
[TBL] [Abstract][Full Text] [Related]
12. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
Ison MG; Portsmouth S; Yoshida Y; Shishido T; Mitchener M; Tsuchiya K; Uehara T; Hayden FG
Lancet Infect Dis; 2020 Oct; 20(10):1204-1214. PubMed ID: 32526195
[TBL] [Abstract][Full Text] [Related]
13. Baloxavir marboxil in Japanese patients with seasonal influenza: Dose response and virus type/subtype outcomes from a randomized phase 2 study.
Watanabe A; Ishida T; Hirotsu N; Kawaguchi K; Ishibashi T; Shishido T; Sato C; Portsmouth S; Tsuchiya K; Uehara T
Antiviral Res; 2019 Mar; 163():75-81. PubMed ID: 30684563
[TBL] [Abstract][Full Text] [Related]
14. Baloxavir heralds a new era in influenza virus biology.
Kikuchi T; Watanabe A
Respir Investig; 2019 Jan; 57(1):1-2. PubMed ID: 30396860
[TBL] [Abstract][Full Text] [Related]
15. Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan.
Hirotsu N; Sakaguchi H; Fukao K; Kojima S; Piedra PA; Tsuchiya K; Uehara T
BMC Pediatr; 2023 Jan; 23(1):35. PubMed ID: 36681802
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza.
Koshimichi H; Tsuda Y; Ishibashi T; Wajima T
J Pharm Sci; 2019 May; 108(5):1896-1904. PubMed ID: 30557562
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of baloxavir marboxil for the treatment of influenza in Japanese clinical practice: A postmarketing surveillance of more than 3000 patients.
Nakazawa M; Hara K; Komeda T; Ogura E
J Infect Chemother; 2020 Jul; 26(7):729-735. PubMed ID: 32409018
[TBL] [Abstract][Full Text] [Related]
18. Baloxavir marboxil, Fremanezumab-vfrm, Galcanezumab-gnlm, and Lofexidine hydrochloride.
Hussar DA; Moyer MR
J Am Pharm Assoc (2003); 2019; 59(1):141-144. PubMed ID: 30580925
[No Abstract] [Full Text] [Related]
19. Baloxavir marboxil: the new influenza drug on the market.
O'Hanlon R; Shaw ML
Curr Opin Virol; 2019 Apr; 35():14-18. PubMed ID: 30852344
[TBL] [Abstract][Full Text] [Related]
20. Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.
Uehara T; Hayden FG; Kawaguchi K; Omoto S; Hurt AC; De Jong MD; Hirotsu N; Sugaya N; Lee N; Baba K; Shishido T; Tsuchiya K; Portsmouth S; Kida H
J Infect Dis; 2020 Jan; 221(3):346-355. PubMed ID: 31309975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
